Dentsply Sirona price target lowered to $16 from $20 at Piper Sandler

Piper Sandler lowered the firm’s price target on Dentsply Sirona (XRAY) to $16 from $20 and keeps a Neutral rating on the shares. Shares are cheap and investor confidence appears low, the firm notes. The difference between Dentsply and other inexpensive medtech stocks is that Piper believes the path to improving performance for peers is cleaner with fewer distractions. The firm will acknowledge that it may not take much for the stock to recapture a modicum of its multiple, but the combination of tariffs and challenges in key end markets leave it believing that rebound isn’t developing near-term.